ASSAY DEVELOPMENT CONSULTING SERVICES FOR NINDS' HEAL PROGRAM.

化验技术进展 预计化验开发顾问将提供高级过程化学专业知识，并通过电话会议和电子邮件向NIH和LDT成员提供关于项目的反馈和指导。过程化学顾问的角色可能包括但不限于以下职责和任务： ·可能需要顾问对生物活性分析进行评估，并建议优化和/或验证用于药物化学活动的分析的策略和实验。 ·可请化验发展顾问协助建立与化验优化或验证有关的里程碑。 ·可能需要顾问就常用的活体测试的设计和解释提供指导，如认知和行为测试。 ·担任化验开发专家，以确定潜在的发展挑战，并提出战略，以便在现实的时间表内应对这些挑战。 ·与其他顾问、承包商和NIH工作人员合作，提供建议、战略规划和管理项目，以促进领导优化、IND支持和临床研究。 ·作为资源，领导开发团队成员满足化验要求，并为小分子化合物从临床前阶段到临床初始阶段进行药物开发活动提供后勤支持。 ·与其他顾问、承包商和NIH工作人员合作，提供建议、战略规划和管理项目，以促进领导优化、IND支持和临床研究。 ·作为资源，领导开发团队成员满足化验要求，并为小分子化合物从临床前阶段到临床初始阶段进行药物开发活动提供后勤支持。 ·合作设计调查性研究，以支持开发化合物。 这项研究是NIH帮助结束成瘾长期(Hear)倡议的一部分，该倡议旨在加快科学解决方案，以了解疼痛的基础并加强临床疼痛管理。这是该计划的一部分，该计划为各种疼痛状况建立了新的治疗选择，以提高生活质量和减少阿片类药物依赖。该项目研究范围广泛的疼痛状况，包括慢性重叠疼痛状况、慢性肌肉骨骼疼痛、围手术期疼痛和膝骨性关节炎。

Assay Development Assay Development consultants will be expected to provide senior-level Process Chemistry expertise and contribute feedback and guidance on projects to the NIH and to LDT members through conference calls and by email. The role of the Process Chemistry consultant may include but is not limited to the following responsibilities and tasks: • Consultants may be required to evaluate bioactivity assays and recommend strategies and experiments to optimize and/or validate the assays for use in a medicinal chemistry campaign. • Assay development consultants may be asked to assist in the establishment of milestones related to assay optimization or validation. • Consultant may be required provide guidance on the design and interpretation of commonly used in vivo assays, such as cognitive and behavioral tests. • Serve as the assay development expert in order to identify potential developmental challenges and suggest strategies to address these challenges on realistic timelines. • In partnership with other consultants, contractors, and the NIH staff, advise, strategically plan, and manage programs to facilitate lead optimization, IND enabling, and clinical studies. • Serve as a resource to lead development team members for assay requirements, and logistics to conduct drug development activities for small molecule compounds from the preclinical stage through to the initial clinical stage. • In partnership with other consultants, contractors, and the NIH staff, advise, strategically plan, and manage programs to facilitate lead optimization, IND enabling, and clinical studies. • Serve as a resource to lead development team members for assay requirements, and logistics to conduct drug development activities for small molecule compounds from the preclinical stage through to the initial clinical stage. • Collaborate on the design of investigative studies in support of development compounds. This study is part of the NIH’s Helping to End Addiction Long-term (HEAL) initiative to speed scientific solutions to understand the basis of pain and enhance clinical pain management. It’s part of the program that establishes novel treatment options for a variety of pain conditions to improve quality of life and reduce opioid dependency. The program studies a broad range of pain conditions, including chronic overlapping pain conditions, chronic musculoskeletal pain, perioperative pain, and knee osteoarthritis.